<p>紅鶴財富管理公司在第四季度購買了安進公司（NASDAQ:AMGN - 免費報告）股票的新頭寸，根據其最近向證券交易委員會提交的 13F 文件。該基金購買了 1,975 股這家醫療研究公司的股票，價值約為 515,000 美元。</p>
<ul>
<li>MarketBeat 週報 – 12/2 - 12/6</li>
</ul>
<p>其他機構投資者和對沖基金最近也增加或減少了對該公司的持股。Talbot Financial LLC 在第四季度將其在安進的股份增加了 5.6%。Talbot Financial LLC 現在擁有 42,791 股這家醫療研究公司的股票，價值 11,153,000 美元，此前在此期間又購買了 2,274 股。瑞士國家銀行在第三季度將其在安進的持股增加了 0.3%。瑞士國家銀行現在擁有 1,592,233 股這家醫療研究公司的股票，價值 513,033,000 美元，此前在此期間又購買了 5,500 股。資產顧問投資管理公司在第三季度將其在安進的持股增加了 9.0%。資產顧問投資管理公司現在擁有 35,934 股這家醫療研究公司的股票，價值 11,578,000 美元，此前在上個季度又購買了 2,954 股。Principal Financial Group Inc.在第三季度將其在安進的持股增加了 6.0%。Principal Financial Group Inc.現在擁有 635,172 股這家醫療研究公司的股票，價值 204,659,000 美元，此前在此期間又購買了 35,785 股。最後，Ascent Wealth Partners LLC 在第四季度將其在安進的持股增加了 0.7%。Ascent Wealth Partners LLC 現在擁有 9,024 股這家醫療研究公司的股票，價值 2,352,000 美元，此前在上個季度又購買了 64 股。76.50% 的股票由機構投資者持有。</p>
<h2>分析師評級變動</h2>
<p>安進一直是多份研究報告的主題。傑富瑞金融集團在 11 月 12 日的研究報告中重申了對安進的 “買入” 評級，並給出了 380.00 美元的目標價。沃爾夫研究在 11 月 15 日的研究報告中開始覆蓋安進，並對該股票給予了 “同行表現” 的評級。Redburn Partners 在 11 月 27 日的報告中將安進的目標價從 200.00 美元下調至 195.00 美元。花旗集團在 2 月 5 日的報告中重申了對安進的 “中性” 評級。最後，瑞銀集團在 2 月 12 日的報告中重新發布了對安進的 “持有” 評級。有兩位研究分析師對該股票給予了賣出評級，十位給予了持有評級，十二位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，安進目前的平均評級為 “持有”，平均目標價為 314.09 美元。</p>
<ul>
<li>安進股票因減肥藥數據下跌：反應過度還是合理？</li>
</ul>
<p><strong>閲讀我們對安進的最新分析</strong></p>
<h2>安進的內部交易</h2>
<p>在其他安進新聞中，執行副總裁 David M. Reese 在 2 月 19 日的交易中出售了 8,711 股公司的股票。股票以 293.22 美元的平均價格出售，總交易額為 2,554,239.42 美元。出售後，該執行副總裁現在直接擁有 62,147 股公司的股票，價值 18,222,743.34 美元。此次交易使其持股減少了 12.29%。該交易已在向 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，高級副總裁 Nancy A. Grygiel 在 2 月 5 日的交易中出售了 1,589 股公司的股票。股票以 304.47 美元的平均價格出售，總交易額為 483,802.83 美元。交易後，該高級副總裁現在直接擁有 7,210 股公司的股票，價值 2,195,228.70 美元。此次交易使其持股減少了 18.06%。該銷售的披露可以在這裏找到。在過去的九十天裏，內部人士出售了 69,341 股公司股票，價值 20,644,335 美元。公司內部人士持有 0.69% 的公司股票。</p>
<h2>安進股票表現</h2>
<ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
<p>NASDAQ:AMGN 週三開盤價為 315.63 美元。安進公司的十二個月低點為 253.30 美元，十二個月高點為 346.85 美元。該公司的速動比率為 0.95，流動比率為 1.26，債務與股本比率為 9.62。該股票的 50 日簡單移動平均為 278.13 美元，200 日簡單移動平均為 300.16 美元。該公司的市值為 1695.6 億美元，市盈率為 41.81，市盈增長比率為 2.63，貝塔值為 0.56。</p>
<p>安進（NASDAQ:AMGN - 獲取免費報告）最近在 2 月 4 日發佈了季度財報。這家醫療研究公司報告每股收益為 5.31 美元，超出分析師一致預期的 5.04 美元，超出幅度為 0.27 美元。安進的淨利潤率為 12.24%，股本回報率為 176.32%。分析師預計安進公司在當前財政年度將發佈 20.62 的每股收益。</p>
<h2>安進增加股息</h2>
<p>該公司最近還宣佈了一項季度股息，將於 3 月 7 日（星期五）支付。2 月 14 日（星期五）的股東將獲得每股 2.38 美元的股息。這相當於年化股息 9.52 美元，股息收益率為 3.02%。該股息的除息日為 2 月 14 日（星期五）。這比安進之前的季度股息 2.25 美元有所增加。安進目前的派息比率為 126.09%。</p>
<h2>關於安進</h2>
<p>（免費報告）</p>
<p>安進公司在全球範圍內發現、開發、生產和交付人用治療藥物。公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔；用於治療成年斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的 Otezla；用於治療絕經後女性骨質疏鬆症的 Prolia；用於預防骨骼相關事件的 XGEVA；可降低心肌梗死、中風和冠狀動脈再血管化風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票，勝過安進</li>
<li>ETF 會支付股息嗎？你需要知道的事項</li>
<li>Tempus AI 是一個買入機會，如果你能承受波動性</li>
<li>股票情緒分析：它是如何工作的</li>
<li>大規模回購：三隻向股東返還大量現金的股票</li>
<li>三個股票代碼引領迷因股復興</li>
<li>Nebius 財報後下滑：長期買入機會？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p>
<p><em>此即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在安進嗎？</h2>
<p>在你考慮安進之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而安進並不在名單上。</p>
<p>雖然安進目前在分析師中被評為 “持有” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
<p>在這裏查看這五隻股票</p>

安進

<p>紅鶴財富管理公司（Red Crane Wealth Management LLC）在第四季度通過購買 1,975 股，獲得了價值約 515,000 美元的安進（Amgen Inc.，NASDAQ:AMGN）新頭寸。其他機構投資者，包括 Talbot Financial LLC 和瑞士國家銀行（Swiss National Bank），也增加了對安進的持股。分析師對該股票的評級不一，平均目標價為 314.09 美元。安進的股票表現顯示，過去十二個月的價格區間在 253.30 美元到 346.85 美元之間，目前市值為 1695.6 億美元</p>

<p>Red Crane Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities &amp; Exchange Commission. The fund bought 1,975 shares of the medical research company's stock, valued at approximately $515,000.</p>
<div class="lb-trans"><p>紅鶴財富管理公司在第四季度購買了安進公司（NASDAQ:AMGN - 免費報告）股票的新頭寸，根據其最近向證券交易委員會提交的 13F 文件。該基金購買了 1,975 股這家醫療研究公司的股票，價值約為 515,000 美元。</p>
</div><ul>
<li>MarketBeat Week in Review – 12/2 - 12/6</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 12/2 - 12/6</li>
</ul>
</div><p>Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Talbot Financial LLC boosted its stake in shares of Amgen by 5.6% during the 4th quarter. Talbot Financial LLC now owns 42,791 shares of the medical research company's stock worth $11,153,000 after acquiring an additional 2,274 shares during the period. Swiss National Bank boosted its position in Amgen by 0.3% during the third quarter. Swiss National Bank now owns 1,592,233 shares of the medical research company's stock worth $513,033,000 after purchasing an additional 5,500 shares during the period. Asset Advisors Investment Management LLC increased its holdings in shares of Amgen by 9.0% in the third quarter. Asset Advisors Investment Management LLC now owns 35,934 shares of the medical research company's stock valued at $11,578,000 after purchasing an additional 2,954 shares during the last quarter. Principal Financial Group Inc. raised its position in shares of Amgen by 6.0% in the third quarter. Principal Financial Group Inc. now owns 635,172 shares of the medical research company's stock valued at $204,659,000 after purchasing an additional 35,785 shares during the period. Finally, Ascent Wealth Partners LLC lifted its stake in shares of Amgen by 0.7% during the 4th quarter. Ascent Wealth Partners LLC now owns 9,024 shares of the medical research company's stock worth $2,352,000 after buying an additional 64 shares during the last quarter. 76.50% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他機構投資者和對沖基金最近也增加或減少了對該公司的持股。Talbot Financial LLC 在第四季度將其在安進的股份增加了 5.6%。Talbot Financial LLC 現在擁有 42,791 股這家醫療研究公司的股票，價值 11,153,000 美元，此前在此期間又購買了 2,274 股。瑞士國家銀行在第三季度將其在安進的持股增加了 0.3%。瑞士國家銀行現在擁有 1,592,233 股這家醫療研究公司的股票，價值 513,033,000 美元，此前在此期間又購買了 5,500 股。資產顧問投資管理公司在第三季度將其在安進的持股增加了 9.0%。資產顧問投資管理公司現在擁有 35,934 股這家醫療研究公司的股票，價值 11,578,000 美元，此前在上個季度又購買了 2,954 股。Principal Financial Group Inc.在第三季度將其在安進的持股增加了 6.0%。Principal Financial Group Inc.現在擁有 635,172 股這家醫療研究公司的股票，價值 204,659,000 美元，此前在此期間又購買了 35,785 股。最後，Ascent Wealth Partners LLC 在第四季度將其在安進的持股增加了 0.7%。Ascent Wealth Partners LLC 現在擁有 9,024 股這家醫療研究公司的股票，價值 2,352,000 美元，此前在上個季度又購買了 64 股。76.50% 的股票由機構投資者持有。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>AMGN has been the topic of a number of research reports. Jefferies Financial Group reiterated a &#34;buy&#34; rating and issued a $380.00 price target on shares of Amgen in a research note on Tuesday, November 12th. Wolfe Research started coverage on Amgen in a research report on Friday, November 15th. They issued a &#34;peer perform&#34; rating on the stock. Redburn Partners dropped their price target on Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Citigroup reaffirmed a &#34;neutral&#34; rating on shares of Amgen in a report on Wednesday, February 5th. Finally, UBS Group reissued a &#34;hold&#34; rating on shares of Amgen in a report on Wednesday, February 12th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Amgen currently has an average rating of &#34;Hold&#34; and an average price target of $314.09.</p>
<div class="lb-trans"><p>安進一直是多份研究報告的主題。傑富瑞金融集團在 11 月 12 日的研究報告中重申了對安進的 “買入” 評級，並給出了 380.00 美元的目標價。沃爾夫研究在 11 月 15 日的研究報告中開始覆蓋安進，並對該股票給予了 “同行表現” 的評級。Redburn Partners 在 11 月 27 日的報告中將安進的目標價從 200.00 美元下調至 195.00 美元。花旗集團在 2 月 5 日的報告中重申了對安進的 “中性” 評級。最後，瑞銀集團在 2 月 12 日的報告中重新發布了對安進的 “持有” 評級。有兩位研究分析師對該股票給予了賣出評級，十位給予了持有評級，十二位給予了買入評級，一位給予了強烈買入評級。根據 MarketBeat.com 的數據，安進目前的平均評級為 “持有”，平均目標價為 314.09 美元。</p>
</div><ul>
<li>Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?</li>
</ul>
<div class="lb-trans"><ul>
<li>安進股票因減肥藥數據下跌：反應過度還是合理？</li>
</ul>
</div><p><strong>Read Our Latest Analysis on Amgen</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對安進的最新分析</strong></p>
</div><h2>Insider Transactions at Amgen</h2>
<div class="lb-trans"><h2>安進的內部交易</h2>
</div><p>In other Amgen news, EVP David M. Reese sold 8,711 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total transaction of $2,554,239.42. Following the sale, the executive vice president now directly owns 62,147 shares of the company's stock, valued at $18,222,743.34. The trade was a 12.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Nancy A. Grygiel sold 1,589 shares of the firm's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $304.47, for a total transaction of $483,802.83. Following the transaction, the senior vice president now directly owns 7,210 shares of the company's stock, valued at $2,195,228.70. The trade was a 18.06 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 69,341 shares of company stock worth $20,644,335. Corporate insiders own 0.69% of the company's stock.</p>
<div class="lb-trans"><p>在其他安進新聞中，執行副總裁 David M. Reese 在 2 月 19 日的交易中出售了 8,711 股公司的股票。股票以 293.22 美元的平均價格出售，總交易額為 2,554,239.42 美元。出售後，該執行副總裁現在直接擁有 62,147 股公司的股票，價值 18,222,743.34 美元。此次交易使其持股減少了 12.29%。該交易已在向 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，高級副總裁 Nancy A. Grygiel 在 2 月 5 日的交易中出售了 1,589 股公司的股票。股票以 304.47 美元的平均價格出售，總交易額為 483,802.83 美元。交易後，該高級副總裁現在直接擁有 7,210 股公司的股票，價值 2,195,228.70 美元。此次交易使其持股減少了 18.06%。該銷售的披露可以在這裏找到。在過去的九十天裏，內部人士出售了 69,341 股公司股票，價值 20,644,335 美元。公司內部人士持有 0.69% 的公司股票。</p>
</div><h2>Amgen Stock Performance</h2>
<div class="lb-trans"><h2>安進股票表現</h2>
</div><ul>
<li>2 Generic Drug Stocks Ready to Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只准備在 2025 年飆升的仿製藥股票</li>
</ul>
</div><p>NASDAQ:AMGN opened at $315.63 on Wednesday. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62. The stock's 50-day simple moving average is $278.13 and its 200 day simple moving average is $300.16. The firm has a market capitalization of $169.56 billion, a PE ratio of 41.81, a price-to-earnings-growth ratio of 2.63 and a beta of 0.56.</p>
<div class="lb-trans"><p>NASDAQ:AMGN 週三開盤價為 315.63 美元。安進公司的十二個月低點為 253.30 美元，十二個月高點為 346.85 美元。該公司的速動比率為 0.95，流動比率為 1.26，債務與股本比率為 9.62。該股票的 50 日簡單移動平均為 278.13 美元，200 日簡單移動平均為 300.16 美元。該公司的市值為 1695.6 億美元，市盈率為 41.81，市盈增長比率為 2.63，貝塔值為 0.56。</p>
</div><p>Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.04 by $0.27. Amgen had a net margin of 12.24% and a return on equity of 176.32%. On average, analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>安進（NASDAQ:AMGN - 獲取免費報告）最近在 2 月 4 日發佈了季度財報。這家醫療研究公司報告每股收益為 5.31 美元，超出分析師一致預期的 5.04 美元，超出幅度為 0.27 美元。安進的淨利潤率為 12.24%，股本回報率為 176.32%。分析師預計安進公司在當前財政年度將發佈 20.62 的每股收益。</p>
</div><h2>Amgen Increases Dividend</h2>
<div class="lb-trans"><h2>安進增加股息</h2>
</div><p>The business also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Friday, February 14th. This is a boost from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is presently 126.09%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了一項季度股息，將於 3 月 7 日（星期五）支付。2 月 14 日（星期五）的股東將獲得每股 2.38 美元的股息。這相當於年化股息 9.52 美元，股息收益率為 3.02%。該股息的除息日為 2 月 14 日（星期五）。這比安進之前的季度股息 2.25 美元有所增加。安進目前的派息比率為 126.09%。</p>
</div><h2>About Amgen</h2>
<div class="lb-trans"><h2>關於安進</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.</p>
<div class="lb-trans"><p>安進公司在全球範圍內發現、開發、生產和交付人用治療藥物。公司的主要產品包括用於治療斑塊型銀屑病、類風濕性關節炎和銀屑病關節炎的恩利昔；用於治療成年斑塊型銀屑病、銀屑病關節炎和與貝赫切特病相關的口腔潰瘍的 Otezla；用於治療絕經後女性骨質疏鬆症的 Prolia；用於預防骨骼相關事件的 XGEVA；可降低心肌梗死、中風和冠狀動脈再血管化風險的 Repatha；用於治療免疫性血小板減少症患者的 Nplate；用於治療複發性或難治性多發性骨髓瘤患者的 KYPROLIS；用於治療紅細胞數量低於正常水平和貧血的 Aranesp；用於治療絕經後男性和女性骨質疏鬆症的 EVENITY；用於治療野生型 RAS 轉移性結直腸癌患者的 Vectibix；用於治療急性淋巴細胞白血病患者的 BLINCYTO；用於治療甲狀腺眼病的 TEPEZZA；以及用於治療慢性難治性痛風的 KRYSTEXXA。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Amgen</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Tempus AI Is a Buy, If You Can Handle the Volatility</li>
<li>Stock Sentiment Analysis: How it Works</li>
<li>Massive Buybacks: 3 Stocks Returning Big Cash to Shareholders</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過安進</li>
<li>ETF 會支付股息嗎？你需要知道的事項</li>
<li>Tempus AI 是一個買入機會，如果你能承受波動性</li>
<li>股票情緒分析：它是如何工作的</li>
<li>大規模回購：三隻向股東返還大量現金的股票</li>
<li>三個股票代碼引領迷因股復興</li>
<li>Nebius 財報後下滑：長期買入機會？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=AMGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍事科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前經過 MarketBeat 編輯團隊的審查。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Amgen Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在安進嗎？</h2>
</div><p>Before you consider Amgen, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮安進之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而安進並不在名單上。</p>
</div><p>While Amgen currently has a &#34;Hold&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然安進目前在分析師中被評為 “持有” 評級，但頂級分析師認為這五隻股票更值得買入。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

紅鶴財富管理有限責任公司在安進公司（NASDAQ:AMGN）持有 51.5 萬美元的頭寸